Measurement of extended half‐life recombinant factor IX products in clinical practice-Reference-Cited by-同舟云学术

Measurement of extended half‐life recombinant factor IX products in clinical practice

Published:2018-12-07 Issue:2 Volume:41 Page:e46-e49
ISSN:1751-5521
Container-title:International Journal of Laboratory Hematology
language:en
Short-container-title:Int J Lab Hematol

Author:

Bowyer Annette E.¹^ORCID,Shepherd M. Fiona¹,Kitchen Steve¹^ORCID,Maclean Rhona M.²,Makris Mike¹³

Affiliation:

1. Department Of CoagulationRoyal Hallamshire Hospital Sheffield UK

2. Sheffield Haemophilia and Thrombosis CentreRoyal Hallamshire Hospital Sheffield UK

3. Cardiovascular ScienceUniversity of Sheffield Sheffield UK

Publisher

Wiley

Subject

Biochemistry, medical,Clinical Biochemistry,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.12953

Reference10 articles.

1. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product

2. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

3. Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rIX‐FP) in the one‐stage assay;St Ledger K;Haemophilia,2016

4. Europe Co.Human Coagulation factor IX. Monograph 1644. Strasbourg: Ph. Eur. 8th Edition.2014.

5. EMA editorWorkshop report: Characterisation of new clotting factor concentrates (FVIII FIX) with respect to potency assays used for labelling and testing of post infusion samples. EMA;2014; London.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09

2. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B;Methods in Molecular Biology;2023

3. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments;Seminars in Thrombosis and Hemostasis;2022-12-06

4. External quality assessment for one‐stage and chromogenic factor IX assays in samples containing Alprolix (rFIXFc) or Idelvion (rIX‐FP) and evidence that UK National External Quality Assessment Scheme for blood coagulation samples are commutable with patient samples;International Journal of Laboratory Hematology;2022-01-17

5. International consensus recommendations on the management of people with haemophilia B;Therapeutic Advances in Hematology;2022-01